Radioactive Compound Shows Promise as Therapy for Metastatic Castration-Resistant Patients

Radioactive Compound Shows Promise as Therapy for Metastatic Castration-Resistant Patients
A PSMA ligand linked to radioactive lutetium-177 (Lu-177) is a promising therapeutic agent to treat patients with metastatic castration-resistant prostate cancer (mCRPC), according to a recent retrospective study. "German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients," published in The Journal of Nuclear Medicine, reveals that nearly half of mCRPC patients responded to therapy with Lu-177-PSMA-617, which largely exceeds the response rates for other third-line treatments. Prostate-specific membrane antigen (PSMA) is found at high levels in prostate cancers — more so in castration-resistant disease and in metastasis
Subscribe or to access all post and page content.

One comment

  1. Barry Braker says:

    19 died during the study period. How long did the rest of them survive? Did they out live the standard metastatic patient or did they fare better than the average late stage patient?

Leave a Comment

Your email address will not be published. Required fields are marked *